Asano Ryuji, Nagami Amon, Fukumoto Yuki, Miura Kaori, Yazama Futoshi, Ito Hideyuki, Sakata Isao, Tai Akihiro
Fushimi Pharmaceutical Co., Ltd, 1676 Nakazu-cho, Marugame, Kagawa 763-8605, Japan.
Faculty of Life and Environmental Sciences, Prefectural University of Hiroshima, 562 Nanatsuka-cho, Shobara, Hiroshima 727-0023, Japan.
Bioorg Med Chem Lett. 2014 Mar 1;24(5):1339-43. doi: 10.1016/j.bmcl.2014.01.054. Epub 2014 Jan 29.
New boron-containing chlorin derivatives 9 and 13 as agents for both photodynamic therapy (PDT) and boron neutron capture therapy (BNCT) of cancer were synthesized from photoprotoporphyrin IX dimethyl ester (2) and L-4-boronophenylalanine-related compounds. The in vivo biodistribution and clearance of 9 and 13 were investigated in tumor-bearing mice. The time to maximum accumulation of compound 13 in tumor tissue was one-fourth of that of compound 9, and compound 13 showed rapid clearance from normal tissues within 24h after injection. The in vivo therapeutic efficacy of PDT using 13 was evaluated by measuring tumor growth rates in tumor-bearing mice with 660 nm light-emitting diode irradiation at 3h after injection of 13. Tumor growth was significantly inhibited by PDT using 13. These results suggested that 13 might be a good candidate for both PDT and BNCT of cancer.
新型含硼二氢卟吩衍生物9和13作为癌症光动力疗法(PDT)和硼中子俘获疗法(BNCT)的药物,由光原卟啉IX二甲酯(2)和L-4-硼苯丙氨酸相关化合物合成。在荷瘤小鼠中研究了9和13的体内生物分布和清除情况。化合物13在肿瘤组织中达到最大积累的时间是化合物9的四分之一,并且化合物13在注射后24小时内从正常组织中快速清除。通过在注射13后3小时用660nm发光二极管照射荷瘤小鼠来测量肿瘤生长速率,评估使用13的PDT的体内治疗效果。使用13的PDT显著抑制了肿瘤生长。这些结果表明,13可能是癌症PDT和BNCT的良好候选药物。